Medical management of langerhans cell histiocytosis from diagnosis to treatment
Open Access
- 11 May 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Pharmacotherapy
- Vol. 13 (9), 1309-1322
- https://doi.org/10.1517/14656566.2012.688028
Abstract
Introduction: Langerhans cell histiocytosis (LCH) is a heterogeneous disease, involving the accumulation of langerhans cells in various organs. The physician's perception of the disease varies considerably depending on their experience, the presentation of the disease or the short-term treatment outcome. As this disease is very rare, only a limited number of large surveys exist in the literature and many aspects of the management of patients remain obscure or controversial. Areas covered: An expert opinion on the diagnosis and medical management of LCH is presented in this paper. The diagnostic procedures, including differential diagnosis, initial clinical workup and criteria for initiating therapy are reviewed, as well as disease evaluation criteria and therapeutic approaches. Controversial issues in the medical management of LCH patients (aged less than 18 years) are also briefly discussed. Expert opinion: Further fundamental and clinical research is still needed in this field. Progress may be expected from collaborations organized at national and international levels, among collaborative groups and expert networks. Collections of tissue and blood samples in biobanks must also be organized. New international protocols will be opened to patient accrual and represent an opportunity to further develop global research.Keywords
This publication has 58 references indexed in Scilit:
- Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective studyOrphanet Journal of Rare Diseases, 2011
- Recurrent BRAF mutations in Langerhans cell histiocytosisBlood, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- Selectively Targeting Mutant BRAF in Thyroid CancerJournal of Clinical Endocrinology & Metabolism, 2010
- Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinosidePediatric Blood & Cancer, 2009
- Cholesteatoma Secondary to Temporal Bone Involvement by Langerhans Cell HistiocytosisOtology & Neurotology, 2009
- Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosisEuropean Journal of Cancer, 2006
- Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunctionEuropean Journal of Cancer, 2005
- Mutations of the BRAF gene in human cancerNature, 2002
- Topical nitrogen mustard: An effective treatment for cutaneous Langerhans cell histiocytosisThe Journal of Pediatrics, 1991